TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Generex's Insulin Product: When a Company Misrepresents 'Compassionate Use' Derek Lowe submits: Adam Feuerstein schools the Generex (GNBT) folks on what a "Treatment IND" really means, quoting chapter and verse from the FDA. The company's fans have made much of that designation for its flagship buccal insulin product. As has the company's CEO - but that link shows her making statements at investor conferences which are, on the face of them, in flat contradiction to the FDA's own understanding of such matters. The article's worth reading even if you don't give two hoots about Generex, since it'll give you an understanding of what it means (and doesn't mean) when a company has a product designated for "compassionate use". It can also give you an understanding of what it means when a company misrepresents that status, but I think a lot of people here already know what that must mean. . .Complete Story » seekingalpha.com |
Senate Acts to Block Doctors' Medicare Payment Cut Senate Democrats and Republicans agreed to postpone by six months scheduled cuts in Medicare payments to doctors. online.wsj.com |
Biotech: Update on Deals, Mergers, Funding The Burrill Report submits: By Marie DaghlianNutritional supplements may have passed their media heyday but they are still big business. This week private equity firm The Carlyle Group decided to beef up its portfolio by acquiring NBTY (NTY), a global nutritional supplements company that markets products under the names Nature's Bounty, Vitamin World, and Puritan's Pride, in a transaction valued at $3.8 billion. Carlyle, which has assets of more than $90.5 billion under management, will pay $55 per share in cash for all outstanding common shares of NBTY, representing a premium of approximately 57 percent over NBTY's average closing share price during the 30 trading days ended July 14, 2010. The transaction is expected to close by the end of 2010. The announcement triggered a 43 percent jump in NBTY’s shares to $53.74. Complete Story » seekingalpha.com |
Health Outlays Still Seen Rising The health-care overhaul enacted last spring won't significantly change national health spending over the next decade compared with projections before the law was passed. online.wsj.com |
J&J Is Faulted on Recall Timing Johnson & Johnson should have moved sooner to recall some Motrin pills that it discovered were defective in late 2008, a federal official said in prepared testimony. online.wsj.com |